Skip to main content

20th International Myeloma Workshop Main banner

MRD Assessment and role in Myeloma

MRD Assessment and role in Myeloma

Type here to filter the list

P-068: IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS
P-069: Liquid biopsy monitoring is more sensitive than alternative techniques in extramedullary multiple myeloma
P-070: Failure to Clear Circulating Tumor Cells After One Week of Daratumumab, Bortezomib and Dexamethasone is Associated with a Reduced Progression-Free Survival for Myeloma Patients
P-071: Hevylite in the multiple myeloma patient pathway
P-072: Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing
P-073: Modelling multiple myeloma using best clinical response to treatment to predict overall survival
P-074: Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients
P-075: Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience
P-076: The impact of heterogeneous disease distribution on MRD detection in patients with relapsed multiple myeloma
P-077: High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping
P-078: MRDeep Study: Measurable Residual Disease rates in patients with Multiple Myeloma who achieved complete response in 2nd or 3rd lines of treatment.
P-079: Impact of treatment effect on measurable residual disease (MRD) and progression-free survival (PFS): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM)
P-080: Clinical implication of MRD measurement by DuraClone in patients with transplant-eligible, real-world-based study, CAREMM-2104
P-081: Sensitive detection of M-proteins and FLC in blood for diagnosis and monitoring of multiple myeloma
P-082: Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study
P-083: The role of minimal residual disease evaluation for patients with multiple myeloma
P-084: Use of Peripheral Blood for MRD Assessment During Maintenance Therapy: UTSW Experience
P-085: The Use of Clonotypic Mass Spectrometry for Post-AHCT Blood-Based Measurable Residual Disease Monitoring in Patients with Light Chain Multiple Myeloma
P-086: Patient and Haematologist Perspectives of Minimal Residual Disease Testing in Myeloma
P-087: Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: Analysis of MagnetisMM-3
P-494: Euroflow-based ultrasensitive detection of malignant plasma cells in the bone marrow.